Patients with EDIL3 expression were more likely to have the mucinous adenocarcinoma subtype (17.6% vs. 2.3%) and less likely to have the solid adenocarcinoma subtype (11.8% vs. 22.1%) than were EDIL3-negative patients (P = 0.004; Table 4). Here, EDIL3 is linked to mucinous adenocarcinoma.